2025 Endothelin Receptor Antagonist Pipeline Insights for 10+ Companies and 15+ Pipeline Drugs, Including Zibotentan (AstraZeneca), SC0062 (Biocity Biopharmaceutics), and GMA301 (Gmax Biopharm)

Core Insights - The report titled "Endothelin Receptor Antagonist - Pipeline Insight, 2025" provides a comprehensive overview of the current landscape of Endothelin Receptor Antagonist drugs in development, highlighting over 10 companies and more than 15 pipeline drugs [1][2] Company and Drug Development - Companies and academic institutions are actively addressing challenges and exploring opportunities in Endothelin Receptor Antagonist research and development [3] - Approximately 10+ key companies are involved in developing therapies for Endothelin Receptor Antagonists, with AstraZeneca having drug candidates in the advanced Phase III stage [9] - The report details various drugs at different clinical development stages, including Phase II, I, preclinical, and discovery [4][11] Emerging Drugs - Zibotentan, developed by AstraZeneca, is a novel oral tablet aimed at blocking the endothelin pathway to slow tumor growth in various cancers and is currently in Phase III for Chronic Kidney Disease [5] - SC0062, developed by Biocity Biopharmaceutics, is a highly selective ETA receptor antagonist showing promise in improving long-term safety for chronic kidney disease patients and is in Phase II for Diabetic kidney disease and IgA Nephropathy [6] - GMA301, a humanized monoclonal antibody from Gmax Biopharm, targets pulmonary artery hypertension and has received orphan drug designation from the FDA, currently in Phase I trials [7] Therapeutic Assessment - The report categorizes Endothelin Receptor Antagonist drugs based on product type, stage, route of administration, and molecule type, providing insights into the therapeutic landscape [8][10] - The analysis includes details on collaborations, acquisitions, and licensing activities related to the development of Endothelin Receptor Antagonist therapeutics [12] Key Questions Addressed - The report answers critical questions regarding the number of companies developing Endothelin Receptor Antagonist drugs, the stages of development for these drugs, and recent trends in the industry [17]